A mouse model of transplanted
hepatoma H22 was used in this study to evaluate the synergic and attenuating effects of ESB in
chemotherapy.
Tumor inhibition rate, life span of mice and the toxicity of
chemotherapy were observed. The
body weight,
tumor weight, thymus index and spleen index in H22-bearing mice were also measured. The phagocytotic function of macrophages was studied by observing phagocytization of peritoneal macrophages.
RESULTS: The increase of
body weight in
5-FU plus ESB groups was higher than that in
5-FU group, and the side effects such as
anorexia, abdominal distention and athrepsy were relieved. Compared with untreated group, prolonged lifetime in
5-FU plus high-dose ESB group and
5-FU plus low-dose ESB group was improved.
Life prolongation rates in
5-FU plus high-dose ESB group and
5-FU plus low-dose ESB group were 61.46% and 23.59% respectively. High-dose ESB,
5-FU,
5-FU plus low-dose ESB and
5-FU plus high-dose ESB could inhibit the
tumor growth, and the
tumor inhibition rates were 36.98%, 42.26%, 52.45% and 65.28%, respectively. Thymus index and spleen index were increased significantly in
5-FU plus low-dose ESB group and
5-FU plus high-dose ESB group. White blood cell (WBC) count was decreased obviously in
5-FU group, while the count of WBC was increased in
5-FU plus low-dose ESB group and
5-FU plus high-dose ESB group. The phagocytotic function of macrophages was also increased in
5-FU plus low-dose ESB group and
5-FU plus high-dose ESB group.
CONCLUSION: